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Abstract
Malignant ameloblastoma (metastatic ameloblastoma, MA) is currently defined as a distinct pathologic entity, MA,
despite its histologically benign appearance. According to the new criteria, the histological and clinical features of
MA are more homogenous. Here, we report three cases of histologically confirmed pulmonary MA. Two of the
three patients complained of chest pain as the primary symptom, and the other case was detected upon the
evaluation of pulmonary nodules found during a health examination after a local recurrence of mandible
ameloblastoma. All three patients were female with an average age of 48 years. The intervals between the primary
ameloblastoma and metastasis to the lung were 14 years, 19 years and 10 years, averaging 14.3 years. Prior to
metastasis to the lung, only one patient experienced local recurrences, at 5 and 19 years after the primary tumor
resection, while the other two patients both remained disease-free. Computed tomography (CT) or X-ray evaluation
demonstrated multiple bilateral lung nodules ranging in size from several millimeters up to 2 cm. Histologically, the
pulmonary metastatic tumors showed a unique growth pattern: the tumor cells grew among the interstitial alveoli
but did not appear to destructively infiltrate the surrounding tissue. Immunohistochemically, the MA cells expressed
squamous differentiation markers, such as CK10/13 and p63, while the alveolar epithelial cells stained for TTF1 and
PE10. In this paper, we discuss the clinical behavior, differential diagnosis and unique growth pattern of pulmonary MA.
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Background
Ameloblastoma is a rare odontogenic epithelial tumor
that represents only approximately 1 % of all jaw tumors,
but it is the second-most common odontogenic tumor.
Although it is always considered a benign odontogenic
tumor, ameloblastoma is slow growing, locally aggres-
sive, and has a high propensity for local recurrence if
not removed completely. Some authors tend to regard it
as a potentially malignant tumor [1, 2], but metastasis is
rare. However, a histologically benign-appearing amelo-
blastoma can metastasize to local lymph nodes or other
distant organs, such as the brain, lung, skin, etc. Over a
decade can pass before metastatic tumors are observed
after the resection of the primary tumor [3, 4]. Histo-
logic appearance alone cannot indicate late metastasis.
Because of its complex behavior, ameloblastoma con-
tinues to be a subject of intense interest and some
controversy.
The WHO classification of odontogenous tumors
(2005) currently defines malignant ameloblastoma (MA)
as “an ameloblastoma that metastasizes in spite of a be-
nign histological appearance.” Ameloblastoma with cyto-
logical atypia is defined as ameloblastic carcinoma even
if metastasis is absent. Thus, MA is defined as a retro-
spective diagnosis that can only be made when metasta-
sis occurs. In many cases, MA not only maintains the
histological characteristics of the parent tumor but also
continues to display similarly indolent clinical behavior.
However, the histological features of MA of the lung are
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seldom discussed in the literature. Because of the low
frequency of MA and its unclear clinical history, physi-
cians should avoid misdiagnosing MA as other primary
or metastatic tumors of the lung.
Case Presentation
Patients and samples
This study included 3 patients from the Department of
Pathology, Fudan University Shanghai Cancer Center,
who were diagnosed between 2010 and 2014. Patient 1
was an inpatient of our hospital, and patients 2 and 3
were accepted for consultation. The clinical information
and gross features were collected from the referring hos-
pitals and the case files of our hospital. Formalin-fixed
paraffin-embedded tissue blocks or unstained slides for
the consultation cases were reprocessed for
hematoxylin-eosin staining and immunohistochemistry.
Slides of one of the local recurrences of patient 2’s man-
dible tumor were also available. Follow-up information
was available in all three cases.
Immunohistochemistry
Immunohistochemistry was performed on three pul-
monary MAs and one mandible ameloblastoma. Cyto-
keratin (dilution 1:150, Dako, clone AE1/AE3), EMA
(dilution 1:100, Dako, clone E29), CK7 (dilution 1:200,
Dako, clone OV-TL12/30), p63 (dilution 1:50, Dako,
clone 4A4), TTF-1 (dilution 1:100, Leica, clone SPT24),
SP-A (dilution 1:50, LongIsland, PE10), CK5/6 (dilution
1:200, Dako, D5/16 B4), CK10/13 (dilution 1:100, Dako,
DE-K13), and vimentin (dilution 1:1000, clone V9, Dako)
were all used a Ventana Benchmark XT autostainer
(Ventana Medical Systems Inc., Tucson, AZ, USA). Ap-
propriate positive and negative controls were included.
Results
Clinicopathological data (Table 1)
The three female patients were 52, 48 and 44 years old
(mean, 48 years old) at the time of the confirmation of
the metastatic lung tumor. Two patients experienced
chest pain as the primary symptom (case 1 and 3) and
did not have a history of odonto-tumors. Patient 2 had
undergone routine examinations due to the local recur-
rences after the original surgery for ameloblastoma
19 years ago. We investigated the clinical histories of the
other two patients and determined that they had under-
gone ameloblastoma surgery approximately 14 years and
10 years before. All primary tumors were located in the
mandible and metastasized to the lung after 10-19 years
(mean, 14.3 years). X-ray and CT imaging showed mul-
tiple nodules in the bilateral lungs that measured several
mm up to 2 cm in three cases (Fig. 1) and were mainly
located in the right lung in patient 2. They demonstrated
some lobular or irregular shape nodules with invariable
sizes in radiology. X-ray of recurrent ameloblastoma in
patient 2 showed a cystic radiolucency with scalloped
and hyperostotic borders, which was below the former
surgical region involving the inferior border of mandible
with expansile destruction of the inferior mandibular
cortex (Fig. 1). Positron emission tomography (PET)-CT
showed that the fluorodeoxyglucose (F18-FDG) metabol-
ism of the nodules was normal in patients 1 and 3.
Tumor markers in serum for lung cancer, including
SCC, NSE, CA125, CEA, Cyfra21-1 were normal in all
the three cases. One nodule in each patient was removed
with a thoracoscopy for biopsy. No subsequent therapy
was administered.
The two consultation cases were initially not clearly
diagnosed and were thought to be benign lesions be-
cause of the unremarkable morphology (cases 2 and 3).
The morphological description for patient 1 was based
solely on the frozen section diagnosis.
Patient 1 was biopsied at our hospital. Grossly, the
nodule was relatively soft and well circumscribed from
the surrounding lung tissue. The cut surface was solid,
grey and white, without obvious cysts or necrosis.
Histologically, the pulmonary nodules of the three pa-
tients were all well circumscribed and interspersed by
many glandular/papillary structures and cellular cords or
nests (Fig. 2a and Fig. 2b). The glandular/papillary
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elements consisted of columnar or cuboidal epithelial
cells with some serous secretions in the lumens. The cel-
lular nests among the glandular/papillary structures con-
tained mostly spindle or ovoid tumor cells with a poorly
defined cytoplasm (Fig. 2c). Focal squamous metaplasia
could be observed (Fig. 2d). Cytological atypia, mitosis
and necrosis were absent. However, the mesenchymal el-
ements of the primary “ameloblastic fibroma” according
to the original diagnosis were absent from the metastatic
tumor in patient 1. In patient 2, the locally recurrent le-
sion of the left mandible demonstrated the classic mor-
phological features of a solid/multicystic ameloblastoma.
The ameloblastoma nests consisted of stellate cells with
peripheral palisading that mainly represented a follicular
growth pattern. The nests were separated by a fibroblas-
tic stroma. Many tumor nests demonstrated central
squamous metaplasia and keratin pearl formation, which
is characteristic of acanthomatous ameloblastoma. The
infiltration of the local bone was observed. Compared
with the local recurrent tumor, the pulmonary metastatic
tumor appeared more cellular. In patient 3, further
pathological details of the primary ‘ameloblastoma’ could
not be obtained. In addition to the morphology de-
scribed above, larger sheets of ameloblastoma cells with
small squamous epithelium-covered cysts were observed
in the pulmonary tumor.
Immunohistochemistry
Immunohistochemical staining showed that the glandu-
lar/papillary elements were AE1/AE3+, EMA+, CK7+,
TTF-1+ (Fig. 3a), PE10+ (Fig. 3b), p63-, CK5/6-, CK10/
13-, and vimentin-, which demonstrated that they were
alveolar epithelial cells. Moreover, the nested spindle/
ovoid tumor cells among the alveoli were AE1/AE3+,
EMA+, CK7-, TTF-1-, PE10-, p63+ (Fig. 3d), CK5/6+,
CK10/13+ (Fig. 3c), and vimentin-. These immuohisto-
chemical staining results indicated that the nested
Fig. 1 X-ray and CT findings of MA. (a) and (b): X-ray and CT showing bilateral pulmonary nodules in patient 1. (c): CT scan showing bilateral pul-
monary nodules that are mainly located in the right lung in patient 2. (d): X-ray of recurrent ameloblastoma in patient 2 showing a cystic radio-
lucency with scalloped and hyperostotic borders below the former surgical region involving the inferior border of mandible. Expansile
destruction of the inferior mandibular cortex was seen. (e): CT scan showing bilateral pulmonary nodules in patient 3. The lobular or irregular
round nodules with invariable sizes in all the three cases
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Fig. 2 Histological findings of MA. (a): The locally recurrent tumor showed a solid/multicystic-type ameloblastoma. The tumor nests consisted of
stellate cells with peripheral palisading. The stroma was fibrous. HE × 40. (Case 2). (b): The pulmonary metastatic lesion was more cellular, with a
clear margin between the lesion and the surrounding lung tissue. HE × 40. (c): Spindle cells and oval cells comprised the nests and intercrossed
the margin with glandular structures. (d): Many glandular/papillary structures were observed, among which were sheets of spindle cells with local
squamous metaplasia. Cytological atypia was absent. HE × 100
Fig. 3 Immunohistochemical staining in MA. (a) and (b): The lining epithelial cells of the gadular structures are TTF-1+ and PE10+, indicating the
residual alveolar epithelial cells (×100). (c) Stellate cells are CK10/13+ (×100). (d) The spindle cells are also p63+ (×100)
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spindle/ovoid cells were ameloblastoma elements. The
total Ki-67 index was approximately 1 %.
Follow-up
None of the patients received further treatment from the
time of the lung biopsies to the latest follow-up (March
2015). All three patients presented an eventless course.
The lengths of the follow-up intervals were 57 months,
53 months and 9 months (mean, 39.7 months).
Discussion
Previous studies have reported MA as “malignant”,
“metastatic”, “metastasizing”, “ameloblastoma with me-
tastasis”, etc. and have lacked uniform diagnostic criteria.
Metastasis occurring from “adamantinoma of the jaw”
was also included in this group. MA has been reported
as a heterogeneous clinico-pathological entity that con-
sists of ameloblastomas with different histological and
clinical behaviors—from very aggressive to highly indo-
lent. Because cytological atypia are not excluded from
the early diagnostic criteria for MA, many reported cases
of MA may be malignant entities other than MA [5, 6].
More than 100 cases of so-called MA have been re-
ported since the first report in 1923 by Emura [7]. The
valid identification of MA remains a problem.
However, the current WHO classification of odonto-
genic carcinomas clearly distinguishes between MA and
ameloblastomatic carcinoma using the typical well-
differentiated cellular features of MA [8]. According to
the new definition, MA is less documented in literature.
By reviewing 98 cases of MA reported in the literature,
Van Dam et al. identified only 24 valid cases of MA
based on the printed histological pictures and identified
3 additional cases [1, 6]. They found that MA can be iso-
lated to a more homogenous clinical pathological entity
with special clinical behavior based on histological cri-
teria. They proposed that if aggressive clinic behavior is
observed, such as rapid growth and widespread metasta-
sis, ameloblastic carcinoma or other carcinomas should
be suspected. We reported another 3 cases of pulmonary
MA that were diagnosed using the WHO criteria, simi-
larly to Van Dam.
MA most frequently metastasizes to the lung at a rate
of approximately 75-88 % of metastases, and this rate
does not differ by gender [1, 6, 7]. Approximately 80 %
of the primary sites of pulmonary MA are located in the
mandible, and the remaining cases are maxillary. Pul-
monary MA commonly develops via hematogenous and
lymphatic routes. In addition, a few metastases are as-
sumed to have occurred due to aspiration, because the
tumor grew within the bronchi and bronchioli. This as-
sumption is further sustained because such tumors are
often located in the right lung [9]. The disease-free inter-
val of MA is usually quite long—ranging from 2 months
to 45 years (mean, 14-18 years) [4, 3]. Interestingly, des-
pite many local recurrences and widespread metastatic
tumors, many pulmonary MA cases show indolent clin-
ical behavior with long survival times. Longevity is also
possible [10, 11]. Moreover, patients have died of causes
other than MA metastasis in some vital cases [12]. Sur-
gical excision is the only treatment option, because both
radiotherapy and chemotherapy are ineffective. In cases
of multiple pulmonary metastases, such as our patients,
a wider excision has not been shown to be helpful.
The histological features of pulmonary MA have been
insufficiently discussed in the literature. Henderson et al.
noted that a metastasizing tumor in the lung was more
cellular than the primary tumor [13]. Their histological
pictures showed many glandular structures. The same
morphology was also noted in a micrograph provided by
Mantin O et al. [14]. Chou YH et al. indicated an inter-
esting interstitial growth pattern of the MA cells in the
lung [15]. We also observed this distinctive finding in all
3 of our cases. In case 2, the locally recurrent mandibu-
lar tumor was a solid/multicystic ameloblastoma with a
follicular growth pattern. The nests consisted of a stel-
late reticulum with peripheral palisading basal cells and
local squamous metaplasia separated by fibrous stroma.
The pulmonary metastatic tumor of patient 2 was more
cellular, with many glandular/papillary structures that
did not appear in the primary tumor. Among these
structures, nests of spindle/ovoid cells with peripheral
palisading basal cells and local squamous metaplasia that
resembled acanthomatous ameloblastoma were ob-
served. The primary tumors of patients 1 and 3 were not
available, but the metastatic tumors also presented simi-
lar histological features. The immunochemical staining
results identified the ameloblastoma elements among
the alveoli of the lung.
In our series, these cases were all initially thought to
either clinically or pathologically represent a primary
lung tumor, especially the two patients without a clear
clinical history. After biopsy, the biphasic morphology
initially confounded the preliminary diagnosis. The dif-
ferential diagnosis included sclerosing hemangioma, ad-
enoma and metastatic lesions, such as adenocarcinoma.
We immunohistochemically stained one locally recur-
rent (patient 2) and 3 metastatic tumors in all three
cases. In all tumors, the epithelial components were
positive for cytokeratins. Particularly, the nests of spin-
dle/ovoid cells in both the primary and metastatic tu-
mors were CK5/6+, CK10/13+ and p63+, which
indicated squamous differentiation. Only the pulmonary
metastastic lesions were CK7+, TTF1+ and PE10+,
which highlighted the glandular/papillary structures
composed of hyperplastic alveolar epithelial cells that
may have been stimulated by the non-destructive growth
of the ameloblastoma. This non-destructive pattern may
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at least in part explain the indolent clinical behavior of
pulmonary MA, because the metastatic tumor exists in
the lung as an interstitial growth for a long time. How-
ever, more case observations are needed to support this
hypothesis. Furthermore, the two types of hyperplastic
cells and this unique growth pattern are important clues
for the diagnosis of pulmonary MA.
Because of the limited collection of valid MA cases,
the definite histopathological and clinical features of
pulmonary MA remain to be clarified. Will metastatic
tumors develop different histological patterns? If dedif-
ferentiation occurs in a metastatic tumor [2, 16], should
it still be identified as MA? To our knowledge, certain
benign tumors, such as leiomyoma, can also metastasize
to the lung [17]. Further investigations that focus both
on the histopathology and clinical behavior as well as
the molecular mechanisms of MA are mandatory to elu-
cidate the mysterious nature of this tumor.
Conclusion
MA is too rare to estimate its prognosis. Based on our
results and the cited works, MA presents an indolent
clinical behavior that is often identified more than
10 years after the resection of the primary ameloblas-
toma. In our experience, more active treatment ap-
proaches, such as excision or chemo- or radiotherapy
are not necessary. The key point to the successful treat-
ment of MA is its precise diagnosis in order to distin-
guish it from other primary or metastatic pulmonary
tumors, especially when the clinical history is not clear.
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